Work

Nivolumab (Nivo) + Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.9020

Authors: Martin Reck, Matthew David Hellmann, Luis G. Paz-Ares, Suresh S. Ramalingam, Julie R. Brahmer, Kenneth John O'Byrne, Prabhu Bhagavatheeswaran, Faith Ellen Nathan, Hossein Borghaei

Institutions: German Center for Lung Research, LungenClinic Grosshansdorf, Memorial Sloan Kettering Cancer Center, Hospital Universitario 12 De Octubre, Emory University, Winship Cancer Institute, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Princess Alexandra Hospital, Bristol-Myers Squibb (United States), Fox Chase Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890022474

Cites:

Cited by: 7

Related to: 10